Sichuan Huiyu Pharmaceutical (688553) Fundamentals 2026 — P/E 157.8x, Revenue Analysis | SniperIQ
Sichuan Huiyu Pharmaceutical (688553) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥6.9B, trading at ¥11.09 on the SHH. This SniperIQ fundamentals page covers Sichuan Huiyu Pharmaceutical's valuation (P/E 157.8x, P/B 1.2x), profitability (net margin 2.3%), revenue (¥998M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Sichuan Huiyu Pharmaceutical's market cap?
Sichuan Huiyu Pharmaceutical (688553) has a market capitalization of approximately ¥6.9B, trading at ¥11.09 on the SHH. Market cap moves with the live share price.
What is Sichuan Huiyu Pharmaceutical's P/E ratio?
Sichuan Huiyu Pharmaceutical's trailing twelve-month P/E ratio is 157.8x, with a price-to-book (P/B) of 1.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Sichuan Huiyu Pharmaceutical?
Sichuan Huiyu Pharmaceutical runs a net profit margin of 2.3%, a gross margin of 98.4%, and an operating margin of 0.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Sichuan Huiyu Pharmaceutical generate?
Sichuan Huiyu Pharmaceutical reported revenue of ¥998M for fiscal year 2025, with net income of -¥25M and earnings per share (EPS) of -0.06. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Sichuan Huiyu Pharmaceutical pay a dividend?
Sichuan Huiyu Pharmaceutical offers a trailing dividend yield of about 1.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Sichuan Huiyu Pharmaceutical financially healthy?
Sichuan Huiyu Pharmaceutical carries a debt-to-equity ratio of 0.19x and a current ratio of 2.61x, with a market beta of 0.51. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Sichuan Huiyu Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Sichuan Huiyu Pharmaceutical (688553) the key facts are: market cap ¥6.9B, P/E 157.8x, revenue ¥998M, 52-week range 9.61-19.10811. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Sichuan Huiyu Pharmaceutical's full fundamentals live
Get Sichuan Huiyu Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.